Repros Therapeutics (RPRX) reported a Q1 loss that was slightly higher than analysts had expected due to increased headcount.
The developer of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders said its Q1 loss was $8.5 million, or $0.37 per share, compared to $7.4 million, or $0.41, the year earlier. Analysts polled by Capital IQ had expected a loss of $0.35 per share.
Revenues were $2,000 up from $1,000 a year ago on increased interest income on higher cash balances. Research and development expenses rose 16% on legal expenses, payroll and benefits expenses as well as clinical development expenses.
RPRX was up 0.8% in recent trade, near the lower end of the 52-week range between $13.93 and $29.79.
Latest posts by Kevin Calderon (see all)
- AMD Epyc Processor Units – A Rival for Intel? - Jun 22, 2017
- Climate Change Study Had To Be Postponed Due To The Severe Ice Conditions - Jun 15, 2017
- Aldi Is Planning On Increasing Its Presence In The US Market - Jun 12, 2017